Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
EJNMMI Research
Published in: EJNMMI Research 1/2020

Open Access 01-12-2020 | Schizophrenia | Original research

In vivo glucose metabolism and glutamate levels in mGluR5 knockout mice: a multimodal neuroimaging study using [18F]FDG microPET and MRS

Authors: Yo-Han Joo, Yun-Kwan Kim, In-Gyu Choi, Hyeon-Jin Kim, Young-Don Son, Hang-Keun Kim, Paul Cumming, Jong-Hoon Kim

Published in: EJNMMI Research | Issue 1/2020

Login to get access

Abstract

Background

Perturbed functional coupling between the metabotropic glutamate receptor-5 (mGluR5) and N-methyl-d-aspartate (NMDA) receptor-mediated excitatory glutamatergic neurotransmission may contribute to the pathophysiology of psychiatric disorders such as schizophrenia. We aimed to establish the functional interaction between mGluR5 and NMDA receptors in brain of mice with genetic ablation of the mGluR5.

Methods

We first measured the brain glutamate levels with magnetic resonance spectroscopy (MRS) in mGluR5 knockout (KO) and wild-type (WT) mice. Then, we assessed brain glucose metabolism with [18F]fluorodeoxyglucose ([18F]FDG) positron emission tomography before and after the acute administration of an NMDA antagonist, MK-801 (0.5 mg/kg), in the same mGluR5 KO and WT mice.

Results

Between-group comparisons showed no significant differences in [18F]FDG standardized uptake values (SUVs) in brain of mGluR5 KO and WT mice at baseline, but widespread reductions in mGluR5 KO mice compared to WT mice after MK-801 administration (p < 0.05). The baseline glutamate levels did not differ significantly between the two groups. However, there were significant negative correlations between baseline prefrontal glutamate levels and regional [18F]FDG SUVs in mGluR5 KO mice (p < 0.05), but no such correlations in WT mice. Fisher’s Z-transformation analysis revealed significant between-group differences in these correlations (p < 0.05).

Conclusions

This is the first multimodal neuroimaging study in mGluR5 KO mice and the first report on the association between cerebral glucose metabolism and glutamate levels in living rodents. The results indicate that mGluR5 KO mice respond to NMDA antagonism with reduced cerebral glucose metabolism, suggesting that mGluR5 transmission normally moderates the net effects of NMDA receptor antagonism on neuronal activity. The negative correlation between glutamate levels and glucose metabolism in mGluR5 KO mice at baseline may suggest an unmasking of an inhibitory component of the glutamatergic regulation of neuronal energy metabolism.
Literature
1.
Pellerin L. Food for thought: the importance of glucose and other energy substrates for sustaining brain function under varying levels of activity. Diabetes Metab. 2010;36:S59-63.PubMedCrossRef
2.
Karaca M, Frigerio F, Migrenne S, Martin-Levilain J, Skytt DM, Pajecka K, et al. GDH-dependent glutamate oxidation in the brain dictates peripheral energy substrate distribution. Cell Rep. 2015;13:365–75.PubMedCrossRef
3.
Pellerin L, Magistretti PJ. Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization. PNAS. 1994;91:10625–9.PubMedCrossRefPubMedCentral
4.
Zimmer ER, Parent MJ, Souza DG, Leuzy A, Lecrux C, Kim H-I, et al. [18F]FDG PET signal is driven by astroglial glutamate transport. Nat Neurosci. 2017;20:393–5.PubMedPubMedCentralCrossRef
5.
6.
Barkus C, McHugh SB, Sprengel R, Seeburg PH, Rawlins JNP, Bannerman DM. Hippocampal NMDA receptors and anxiety: at the interface between cognition and emotion. Eur J Pharmacol. 2010;626:49–56.PubMedPubMedCentralCrossRef
7.
Duman RS, Voleti B. Signaling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid-acting agents. Trends Neurosci. 2012;35:47–56.PubMedPubMedCentralCrossRef
8.
Steele D, Moore RL, Swan NA, Grant JS, Keltner NL. Biological perspectives: the role of glutamate in schizophrenia and its treatment. Perspect Psychiatric Care. 2012;48:125–8.CrossRef
9.
Deutschenbaur L, Beck J, Kiyhankhadiv A, Mühlhauser M, Borgwardt S, Walter M, et al. Role of calcium, glutamate and NMDA in major depression and therapeutic application. Prog Neuropsychopharmacol Biol Psychiatry. 2016;64:325–33.PubMedCrossRef
10.
Olloquequi J, Cornejo-Córdova E, Verdaguer E, Soriano FX, Binvignat O, Auladell C, et al. Excitotoxicity in the pathogenesis of neurological and psychiatric disorders: therapeutic implications. J Psychopharmacol. 2018;32:265–75.PubMedCrossRef
11.
12.
Newell KA, Matosin N. Rethinking metabotropic glutamate receptor 5 pathological findings in psychiatric disorders: implications for the future of novel therapeutics. BMC Psychiatry. 2014;14:23.PubMedPubMedCentralCrossRef
13.
Chana G, Laskaris L, Pantelis C, Gillett P, Testa R, Zantomio D, et al. Decreased expression of mGluR5 within the dorsolateral prefrontal cortex in autism and increased microglial number in mGluR5 knockout mice: Pathophysiological and neurobehavioral implications. Brain Behav Immun. 2015;49:197–205.PubMedCrossRef
14.
Shin S, Kwon O, Kang JI, Kwon S, Oh S, Choi J, et al. mGluR5 in the nucleus accumbens is critical for promoting resilience to chronic stress. Nat Neurosci. 2015;18:1017–24.PubMedCrossRef
15.
Tu JC, Xiao B, Naisbitt S, Yuan JP, Petralia RS, Brakeman P, et al. Coupling of mGluR/homer and PSD-95 complexes by the shank family of postsynaptic density proteins. Neuron. 1999;23:583–92.PubMedCrossRef
16.
Chen H-H, Liao P-F, Chan M-H. mGluR5 positive modulators both potentiate activation and restore inhibition in NMDA receptors by PKC dependent pathway. J Biomed Sci. 2011;18:19.PubMedPubMedCentralCrossRef
17.
Lea PM, Custer SJ, Vicini S, Faden AI. Neuronal and glial mGluR5 modulation prevents stretch-induced enhancement of NMDA receptor current. Pharmacol Biochem Behav. 2002;73:287–98.PubMedCrossRef
18.
Alagarsamy S, Sorensen SD, Conn PJ. Coordinate regulation of metabotropic glutamate receptors. Curr Opin Neurobiol. 2001;11:357–62.PubMedCrossRef
19.
Alagarsamy S, Saugstad J, Warren L, Mansuy IM, Gereau RW, Conn PJ. NMDA-induced potentiation of mGluR5 is mediated by activation of protein phosphatase 2B/calcineurin. Neuropharmacology. 2005;49:135–45.PubMedPubMedCentralCrossRef
20.
Chen H-H, Stoker A, Markou A. The glutamatergic compounds sarcosine and N-acetylcysteine ameliorate prepulse inhibition deficits in metabotropic glutamate 5 receptor knockout mice. Psychopharmacology. 2010;209:343–50.PubMedPubMedCentralCrossRef
21.
Gregory KJ, Dong EN, Meiler J, Conn PJ. Allosteric modulation of metabotropic glutamate receptors: structural insights and therapeutic potential. Neuropharmacology. 2011;60:66–81.PubMedCrossRef
22.
Jia Z, Lu Y, Henderson J, Taverna F, Romano C, Abramow-Newerly W, et al. Selective abolition of the NMDA component of long-term potentiation in mice lacking mGluR5. Learn Mem. 1998;5:331–43.PubMedPubMedCentral
23.
Lu Y-M, Jia Z, Janus C, Henderson JT, Gerlai R, Wojtowicz JM, et al. Mice lacking metabotropic glutamate receptor 5 show impaired learning and reduced CA1 long-term potentiation (LTP) but normal CA3 LTP. J Neurosci. 1997;17:5196–205.PubMedPubMedCentralCrossRef
24.
Pietraszek M, Gravius A, Schäfer D, Weil T, Trifanova D, Danysz W. mGluR5, but not mGluR1, antagonist modifies MK-801-induced locomotor activity and deficit of prepulse inhibition. Neuropharmacology. 2005;49:73–85.PubMedCrossRef
25.
Barnes SA, Pinto-Duarte A, Kappe A, Zembrzycki A, Metzler A, Mukamel EA, et al. Disruption of mGluR5 in parvalbumin-positive interneurons induces core features of neurodevelopmental disorders. Mol Psychiatry. 2015;20:1161–72.PubMedPubMedCentralCrossRef
26.
Bhardwaj SK, Ryan RT, Wong TP, Srivastava LK. Loss of dysbindin-1, a risk gene for schizophrenia, leads to impaired group 1 metabotropic glutamate receptor function in mice. Front Behav Neurosci. 2015;9:72.PubMedPubMedCentralCrossRef
27.
Gray L, van den Buuse M, Scarr E, Dean B, Hannan AJ. Clozapine reverses schizophrenia-related behaviours in the metabotropic glutamate receptor 5 knockout mouse: association with N-methyl-d-aspartic acid receptor up-regulation. Int J Neuropsychopharmacol. 2009;12:45–60.PubMedCrossRef
28.
Mirrione MM, Schiffer WK, Fowler JS, Alexoff DL, Dewey SL, Tsirka SE. A novel approach for imaging brain–behavior relationships in mice reveals unexpected metabolic patterns during seizures in the absence of tissue plasminogen activator. NeuroImage. 2007;38:34–42.PubMedCrossRef
29.
Patel S, Hamill TG, Connolly B, Jagoda E, Li W, Gibson RE. Species differences in mGluR5 binding sites in mammalian central nervous system determined using in vitro binding with [18F]F-PEB. Nucl Med Biol. 2007;34:1009–17.PubMedCrossRef
30.
Fang XT, Eriksson J, Antoni G, Yngve U, Cato L, Lannfelt L, et al. Brain mGluR5 in mice with amyloid beta pathology studied with in vivo [11C]ABP688 PET imaging and ex vivo immunoblotting. Neuropharmacology. 2017;113:293–300.PubMedCrossRef
31.
Mlynárik V, Gambarota G, Frenkel H, Gruetter R. Localized short-echo-time proton MR spectroscopy with full signal-intensity acquisition. Magn Reson Med. 2006;56:965–70.PubMedCrossRef
32.
Tkáč I, Starčuk Z, Choi I-Y, Gruetter R. In vivo 1H NMR spectroscopy of rat brain at 1 ms echo time. Magn Reson Med. 1999;41:649–56.PubMedCrossRef
33.
34.
Cudalbu C, Mlynárik V, Gruetter R. Handling macromolecule signals in the quantification of the neurochemical profile. J Alzheimer’s Dis. 2012;31:S101–15.CrossRef
35.
Smith SA, Levante TO, Meier BH, Ernst RR. Computer simulations in magnetic resonance. An object-oriented programming approach. J Magn Reson Ser A. 1994;106:75–105.CrossRef
36.
Govindaraju V, Young K, Maudsley AA. Proton NMR chemical shifts and coupling constants for brain metabolites. NMR Biomed. 2000;13:129–53.PubMedCrossRef
37.
Naressi A, Couturier C, Devos JM, Janssen M, Mangeat C, de Beer R, et al. Java-based graphical user interface for the MRUI quantitation package. MAGMA. 2001;12:141.PubMedCrossRef
38.
Cabanes E, Confort-Gouny S, Le Fur Y, Simond G, Cozzone PJ. Optimization of residual water signal removal by HLSVD on simulated short echo time proton MR spectra of the human brain. J Magn Reson. 2001;150:116–25.PubMedCrossRef
39.
Vanhamme L, van den Boogaart A, Van Huffel S. Improved method for accurate and efficient quantification of MRS data with use of prior knowledge. J Magn Reson. 1997;129:35–43.PubMedCrossRef
40.
Radford KD, Park TY, Jaiswal S, Pan H, Knutsen A, Zhang M, et al. Enhanced fear memories and brain glucose metabolism (18 F-FDG-PET) following sub-anesthetic intravenous ketamine infusion in Sprague-Dawley rats. Transl Psychiatry. 2018;8:1–12.CrossRef
41.
Shirakawa T, Mitsuoka K, Kuroda K, Miyoshi S, Shiraki K, Naraoka H, et al. [18F]FDG-PET as an imaging biomarker to NMDA receptor antagonist-induced neurotoxicity. Toxicol Sci. 2013;133:13–21.PubMedCrossRef
42.
Kosten L, Verhaeghe J, Verkerk R, Thomae D, De Picker L, wyffels L, et al. Multiprobe molecular imaging of an NMDA receptor hypofunction rat model for glutamatergic dysfunction. Psychiatry Res Neuroimaging. 2016;248:1–11.PubMedCrossRef
43.
Tsukada H, Nishiyama S, Fukumoto D, Sato K, Kakiuchi T, Domino EF. Chronic NMDA antagonism impairs working memory, decreases extracellular dopamine, and increases D1 receptor binding in prefrontal cortex of conscious monkeys. Neuropsychopharmacology. 2005;30:1861–9.PubMedCrossRef
44.
Léna I, Chessel A, Le Pen G, Krebs M-O, Garcia R. Alterations in prefrontal glutamatergic and noradrenergic systems following MK-801 administration in rats prenatally exposed to methylazoxymethanol at gestational day 17. Psychopharmacology. 2007;192:373–83.PubMedCrossRef
45.
Roenker NL, Gudelsky GA, Ahlbrand R, Horn PS, Richtand NM. Evidence for involvement of nitric oxide and GABAB receptors in MK-801-stimulated release of glutamate in rat prefrontal cortex. Neuropharmacology. 2012;63:575–81.PubMedPubMedCentralCrossRef
46.
López-Gil X, Artigas F, Adell A. Role of different monoamine receptors controlling MK-801-induced release of serotonin and glutamate in the medial prefrontal cortex: relevance for antipsychotic action. Int J Neuropsychopharmacol. 2009;12:487–99.PubMedCrossRef
47.
Amitai N, Kuczenski R, Behrens MM, Markou A. Repeated phencyclidine administration alters glutamate release and decreases GABA markers in the prefrontal cortex of rats. Neuropharmacology. 2012;62:1422–31.PubMedCrossRef
48.
Olney JW, Labruyere J, Price MT. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science. 1989;244:1360–2.PubMedCrossRef
49.
Kim JH, Lee JO, Lee SK, Moon JW, You GY, Kim SJ, et al. The glutamate agonist homocysteine sulfinic acid stimulates glucose uptake through the calcium-dependent AMPK-p38 MAPK-protein kinase C ζ pathway in skeletal muscle cells. J Biol Chem. 2011;286:7567–76.PubMedCrossRef
50.
Marinangeli C, Didier S, Ahmed T, Caillerez R, Domise M, Laloux C, et al. AMP-activated protein kinase is essential for the maintenance of energy levels during synaptic activation. iScience. 2018;9:1–13.PubMedPubMedCentralCrossRef
51.
Sheikh-Bahaei N, Sajjadi SA, Manavaki R, McLean M, O’Brien JT, Gillard JH. Positron emission tomography–guided magnetic resonance spectroscopy in Alzheimer disease. Ann Neurol. 2018;83:771–8.PubMedCrossRef
52.
Pfund Z, Chugani DC, Juhász C, Muzik O, Chugani HT, Wilds IB, et al. Evidence for coupling between glucose metabolism and glutamate cycling using FDG PET and 1H magnetic resonance spectroscopy in patients with epilepsy. J Cereb Blood Flow Metab. 2000;20:871–8.PubMedCrossRef
53.
54.
Wang H-Y, MacDonald ML, Borgmann-Winter KE, Banerjee A, Sleiman P, Tom A, et al. mGluR5 hypofunction is integral to glutamatergic dysregulation in schizophrenia. Mol Psychiatry. 2020;25:750–60.PubMedCrossRef
55.
Kinney GG, Burno M, Campbell UC, Hernandez LM, Rodriguez D, Bristow LJ, et al. Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents. J Pharmacol Exp Ther. 2003;306:116–23.PubMedCrossRef
56.
Brambilla CR, Veselinović T, Rajkumar R, Mauler J, Orth L, Ruch A, et al. mGluR5 receptor availability is associated with lower levels of negative symptoms and better cognition in male patients with chronic schizophrenia. Hum Brain Mapp. 2020;40:2762–81.CrossRef
57.
Mirbolooki MR, Upadhyay SK, Constantinescu CC, Pan M-L, Mukherjee J. Adrenergic pathway activation enhances brown adipose tissue metabolism: a [18F]FDG PET/CT study in mice. Nucl Med Biol. 2014;41:10–6.PubMedCrossRef
58.
Bilbao A, Falfán-Melgoza C, Leixner S, Becker R, Singaravelu SK, Sack M, et al. Longitudinal structural and functional brain network alterations in a mouse model of neuropathic pain. Neuroscience. 2018;387:104–15.PubMedCrossRef
59.
Lutkenhoff ES, van Erp TG, Thomas MA, Therman S, Manninen M, Huttunen MO, et al. Proton MRS in twin pairs discordant for schizophrenia. Mol Psychiatry. 2010;15:308–18.PubMedCrossRef
60.
Cline GW, Zhao X, Jakowski AB, Soeller WC, Treadway JL. Islet-selectivity of G-protein coupled receptor ligands evaluated for PET imaging of pancreatic β-cell mass. Biochem Biophys Res Commun. 2011;412:413–8.PubMedCrossRef
61.
Patterson S, Irwin N, Guo-Parke H, Moffett RC, Scullion SM, Flatt PR, et al. Evaluation of the role of N-methyl-d-aspartate (NMDA) receptors in insulin secreting beta-cells. Eur J Pharmacol. 2016;771:107–13.PubMedCrossRef
Metadata
Title
In vivo glucose metabolism and glutamate levels in mGluR5 knockout mice: a multimodal neuroimaging study using [18F]FDG microPET and MRS
Authors
Yo-Han Joo
Yun-Kwan Kim
In-Gyu Choi
Hyeon-Jin Kim
Young-Don Son
Hang-Keun Kim
Paul Cumming
Jong-Hoon Kim
Publication date
01-12-2020
Publisher
Springer Berlin Heidelberg
Published in
EJNMMI Research / Issue 1/2020
Electronic ISSN: 2191-219X
DOI
https://doi.org/10.1186/s13550-020-00716-z

Other articles of this Issue 1/2020

EJNMMI Research 1/2020 Go to the issue

Original research

[18F]FDG PET/CT for evaluating early response to neoadjuvant chemotherapy in pediatric patients with sarcoma: a prospective single-center trial

Original research

Pharmacokinetics, radiation dosimetry, acute toxicity and automated synthesis of [18F]AmBF3-TATE

Original research

Neuron-specific enolase has potential value as a biomarker for [18F]FDG/[68Ga]Ga-PSMA-11 PET mismatch findings in advanced mCRPC patients

Original research

Asphericity of tumor FDG uptake in non-small cell lung cancer: reproducibility and implications for harmonization in multicenter studies

Original research

Value of 18F-FDG PET/CT-based radiomics model to distinguish the growth patterns of early invasive lung adenocarcinoma manifesting as ground-glass opacity nodules

Original research

FLT-PET for the assessment of systemic sarcoidosis including cardiac and CNS involvement: a prospective study with comparison to FDG-PET